United States · Bill · HR
H.R. 5313 (106th)
Drug Competition Act of 2000
Introduced
27 September 2000
Last action
—
Status
Referred to the Subcommittee on Health and Environment.
Sponsors
—
Subjects
Discovery layer
Source updated
3 June 2026
Summary
Drug Competition Act of 2000 - Requires brand name drug manufacturers and generic drug manufacturers to notify the Federal Trade Commission and the Attorney General of agreements regarding the sale or manufacture of generic drugs which could have the effect of limiting the research, development, manufacture, marketing, or selling of a generic drug product.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
No timeline events have been ingested for this record yet.
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
3 official files
Introduced in House (text)
Introduced in House (text)
Introduced in House · EN · 27 September 2000
Introduced in House (PDF)
Introduced in House · EN · 27 September 2000
Introduced in House
summary · EN · 27 September 2000
Sponsors
No sponsors or actors listed by the source.
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.congress.gov/bill/106th-congress/house-bill/5313
- Open data entity: https://api.congress.gov/v3/bill/106/hr/5313